An Efficacy and Safety Study of Daratumumab in Patients With Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor [PI] and Immunomodulatory Drug [IMiD]) or Are Double Refractory to a PI and an IMiD

NCT01985126 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

124

Enrollment

INDUSTRY

Sponsor class

Conditions

Multiple Myeloma

Interventions

DRUG: Daratumumab 16 mg/kg (Part 1)
DRUG: Daratumumab 8 mg/kg (Part 1)
DRUG: Methylprednisolone
DRUG: Acetaminophen
DRUG: Diphenhydramine
DRUG: Daratumumab (Part 2)

Sponsor

Janssen Research & Development, LLC